Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for medical industry professionals · Tuesday, October 16, 2018 · 465,272,218 Articles · 3+ Million Readers

Anemia Prevalence Promotes Growth Of Hematology Drugs Market

Global Hematology Drugs Market By Country

Global Hematology Drugs Market By Country

LONDON, GREATER LONDON, UK, October 20, 2017 / -- The Chinese and Japanese markets for drugs to treat blood disorders such as anemia and conditions related to sickle cell disease are the world's fastest-growing. In contrast the markets in countries like France and Australia are only growing slowly. A key difference lies in the prevalence of hemoglobin levels below the normal range in both the Asian countries.
China's market is growing at 16% year on year; Japan's at an only slightly lower 12%. In comparison, the French market is rising at 4%, the Australian at only 3.2% annually. Differences of diet including the preference for rice-based versus wheat-based staples and fish versus red meat have been linked to these differences.
Although hematology drugs are used to treat conditions related to sickle cell disease, rare genetic disorders and other related diseases, treatment of diseases such as anemia is a major part of this market . Major hematology drugs include albumin, epoetin, zoladex, and hyskon.
The global market for hematology drugs is fragmented: nearly three-quarters of sales are attributable to small or medium-sized pharma companies. The market leader is Danish company Novo Nordisk, followed by the UK's Shire and Germany's Bayer.
One of the trends shaping the market is an increase in product approvals for hemophilia. The increase in the number of drug approvals for hemophilia by the regulatory bodies such as FDA in the US is an emerging trend in the market. For instance, in June 2017, Novo Nordisk received FDA approval for its Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) drug that is used in the treatment of hemophilia B. Over the last 17 years, there were no new drug approvals for the treatment of hemophilia. However, there has been an uptake in the approval of new drugs for the treatment of hemophilia. From 2014 to 2017, seven new drugs have been approved by the FDA for treating hemophilia A and B. Increasing number of new FDA approved drugs aids in management of hemophilics and improves their Quality of Life (QoL).

Where to Learn More
Read Hematology Drugs Market Global Report 2017 from The Business Research Company for information on the following:
Markets Covered: Blood Products, Anemia And Other Blood Disorder Drugs
Companies Mentioned: Baxalta, Bayer AG, Novo Nordisk, Pfizer Inc., and Biogen Idec
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Musculoskeletal Disorders Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Interested to know more? Here is a full scope of Biologics and Pharmaceutical Drugs Market reports to explore:
1. Biologics Market Global Report 2017 (
2. Anti-infective Drugs Market Global Report 2017 (
3. Cardiovascular Drugs Market Global Report 2017 (
4. Central Nervous System Drugs Market Global Report 2017 (
5. Dermatology Drugs Market Global Report 2017 (
6. Genito-Urinary Drugs Market Global Report 2017 (
7. Pharmaceutical Drugs Market Global Report 2017 (
8. Metabolic Disorder Drugs Market Global Report 2017 (
9. Musculoskeletal Disorders Drugs Market Global Report 2017 (
10. Ophthalmology Drugs Market Global Report 2017 (
11. Gastrointestinal Drugs Market Global Report 2017 (
12. Respiratory Drugs Market Global Report 2017 (
13. Oncology Drugs Market Global Report 2017 (

About The Business Research Company
Visit The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has research professionals at its office in the UK, India, and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. The Business Research Company’s management have more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world’s largest organizations. The Business Research Company’s Consultant have master’s qualifications from top institutes and include MBAs, MSCs, CFAs and CAs. The Business Research Company’s Consultants gain training and qualifications from the market Research Society and are trained in advanced research practices, techniques, and ethics.

Oliver Guirdham
The Business Research Company
+44 744 3439350
email us here

Powered by EIN Presswire